Publications

Ivan de Kouchkovsky, Li Zhang, Errol Philip, Francis Wright, Daniel Myung Kim, Divya Natesan, Daniel Kwon, Hansen Ho, Son Ho, Emily Chan, Sima P. Porten, Arpita Desai, Franklin W. Huang, Jonathan Chou, David Yoonsuk Oh, Raj Pruthi, Lawrence Fong, Eric Jay Small, Terence W. Friedlander, Vadim S Koshkin. TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors. Journal of Clinical Oncology. 2021. PMID:

Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2021. PMID: 33617937

Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, Usmani SZ. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood cancer journal. 2021. PMID: 33602913

Cheng ML, Lau CJ, Milan MSD, Supplee JG, Riess JW, Bradbury PA, J?nne PA, Oxnard GR, Paweletz CP. Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. JCO precision oncology. 2021. PMID: 34250387

Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, Cameron D, Wright GS, Graas MP, Neven P, Rocca A, Russo S, Krop IE. The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. Breast cancer research and treatment. 2021. PMID: 33591468

Pan D, Coltoff A, Ozbek U, Lin JY, Afshar S, Galitzeck Z, Steinberg A. Evaluating Race and Time to Transplantation in Multiple Myeloma: The Mount Sinai Hospital Experience. Volume 21 of Issue 7 Clinical lymphoma, myeloma & leukemia. 2021. PMID: 33757769

Kober KM, Roy R, Dhruva A, Conley YP, Chan RJ, Cooper B, Olshen A, Miaskowski C. Prediction of evening fatigue severity in outpatients receiving chemotherapy: less may be more. Fatigue : biomedicine, health & behavior. 2021. PMID: 34249477

Ozge Gumusay, Mark Jesus M. Magbanua, Melanie C. Majure, Travis Deal, Jonathan R. Renslo, Chiara A. Wabl, Michelle E. Melisko, A. Jo Chien, Andrei Goga, Mark M. Moasser, John W. Park, Jimmy Hwang, Hope S. Rugo. Abstract PS2-19: Circulating tumor cell (CTC) enumeration in a phase II trial of pazopanib in addition to endocrine therapy in patients with hormone resistant advanced breast cancer (ABC). Cancer research. 2021. PMID:

Errol J. Philip, Sylvia Zhang, Peggy Tahir, Daniel Kim, Francis Wright, Alexander Bell, Hala T. Borno. Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer. 2021. PMID:

Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, Godwin JE, Arellano ML, Sweet KL, Emadi A, Ravandi F, Erba HP, Byrne M, Michaelis L, Topp MS, Vey N, Ciceri F, Carrabba MG, Paolini S, Huls GA, Jongen-Lavrencic M, Wermke M, Chevallier P, Gyan E, Récher C, Stiff PJ, Pettit KM, Löwenberg B, Church SE, Anderson E, Vadakekolathu J, Santaguida M, Rettig MP, Muth J, Curtis T, Fehr E, Guo K, Zhao J, Bakkacha O, Jacobs K, Tran K, Kaminker P, Kostova M, Bonvini E, Walter RB, Davidson-Moncada JK, Rutella S, DiPersio JF. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Volume 137 of Issue 6 Blood. 2021. PMID: 32929488

Lim HC, Gordan JD. Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma. PLoS computational biology. 2021. PMID: 33561166

Kwon DH, Vashisht R, Borno HT, Aggarwal RR, Small EJ, Butte AJ, Huang FW. Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry. Annals of oncology : official journal of the European Society for Medical Oncology. 2021. PMID: 33571636

Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU international. 2021. PMID: 33556233

Li M, Soder R, Abhyankar S, Abdelhakim H, Braun MW, Trinidad CV, Pathak HB, Pessetto Z, Deighan C, Ganguly S, Dawn B, McGuirk J, Dunavin N, Godwin AK. WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1. Volume 10 of Issue 4 Journal of extracellular vesicles. 2021. PMID: 33598108

Lancman G, Lozada K, Athar N, Jacobs S, Doucette J, Cho HJ, Jagannath S, Madduri D, Parekh S, Richard S, Richter J, Chari A. Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2021. PMID: 33716054

Ho C, Svoboda J. Predicting Outcomes following Anti-CD19 CAR T Cell Therapy in Aggressive B Cell Lymphomas. Volume 27 of Issue 3 Transplantation and cellular therapy. 2021. PMID: 33781514

Banerjee R, Lazar AA, Dunn L, Knoche J, Lo M, Arora S, Wong SW, Wolf JL, Martin TG, Dhruva A, Shah N. Benzodiazepine and zolpidem prescriptions during autologous stem cell transplantation. EJHaem. 2021. PMID: 35845271

Jackisch C, Barcenas CH, Bartsch R, Palma JD, Glück S, Harbeck N, Macedo G, O'Shaughnessy J, Pistilli B, Ruiz-Borrego M, Rugo HS. Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. Clinical breast cancer. 2021. PMID: 33678567

Susko MS, Lazar AA, Wang CJ, Van Loon K, Feng M, Hope TA, Behr S, Anwar M. Use of advanced PET-volume metrics predicts risk of local recurrence and overall survival in anal cancer. PloS one. 2021. PMID: 33539412

Tempero M. Learning From Our Mistakes. Journal of the National Comprehensive Cancer Network : JNCCN. 2021. PMID: 33545686